EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy

Ren-Jie Zhao iD, Xing-Xing Fan

International Journal of Molecular Sciences · 08.02.2025 · 26 (4) · 1440

DOI: 10.3390/ijms26041440 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.02.2025. Verfasst von Ren-Jie Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Sc…. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Antibodies, Bispecific, Immunoconjugates. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Macau Science and Technology Development Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-based immune-stimulating drugs (ABIs) represent a transformative frontier in cancer immunotherapy, designed to reshape the tumor microenvironment and overcome immune suppression. This study highlighted recent advances in ABIs, including immune-stimulating antibody conjugates (ISACs), bispecific antibodies (BsAbs), and checkpoint blockade enhancers, with a focus on their mechanisms of action, clinical advancements, and challenges. Preclinical findings revealed that ISACs effectively boost overall anti-cancer immunity by reprogramming tumor-associated macrophages, enhancing T cell activation, and engaging other immune pathways. Similarly, BsAbs effectively redirect immune cells to tumors, achieving significant tumor regression. Additionally, artificial intelligence (AI) is revolutionizing the development of ABIs by optimizing drug design, identifying novel targets, and accelerating preclinical validation, enabling personalized therapeutic strategies. Despite these advancements, significant challenges remain, including immune resistance and off-target effects. Future research should prioritize next-generation multifunctional antibodies, AI-driven innovations, and combination therapies to enhance efficacy and expand therapeutic applications. Connecting these gaps could unlock the full potential of ABIs, upgrading cancer treatment and improving outcomes for patients with refractory or resistant tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyAntibodies, BispecificImmunoconjugatesHumansAnimalsTumor MicroenvironmentImmune Checkpoint InhibitorsArtificial Intelligence

Stichwörter der Autor:innen

antibody-based immune-stimulating drugsartificial intelligencebispecific antibodiesimmune-stimulating antibody conjugates

Substanzen

Antibodies, BispecificImmunoconjugatesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau SAR 999078, China.

ORCID-Profile: Ren-Jie Zhao

Förderung

  • Macau Science and Technology Development Fund Project

Zitieren

APA

Zhao, R. J., & Fan, X. X. (2025). Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy. International Journal of Molecular Sciences, 26(4), 1440. https://doi.org/10.3390/ijms26041440

Vancouver

Zhao RJ, Fan XX. Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy. International Journal of Molecular Sciences. 2025;26(4):1440. doi:10.3390/ijms26041440

BibTeX
@article{Zhao2025,
  author = {Zhao, Ren-Jie and Fan, Xing-Xing},
  title = {Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {4},
  pages = {1440},
  doi = {10.3390/ijms26041440}
}
Kostenlos starten →